RIVAROXABAN TARO 15 MG

Pays: Israël

Langue: anglais

Source: Ministry of Health

Achète-le

Notice patient Notice patient (PIL)
28-09-2023

Ingrédients actifs:

RIVAROXABAN

Disponible depuis:

TARO PHARMACEUTICAL INDUSTRIES LTD

Code ATC:

B01AX06

forme pharmaceutique:

FILM COATED TABLETS

Composition:

RIVAROXABAN 15 MG

Mode d'administration:

PER OS

Type d'ordonnance:

Required

Fabriqué par:

TARO PHARMACEUTICAL INDUSTRIES LTD

Domaine thérapeutique:

RIVAROXABAN

indications thérapeutiques:

Paediatric populationTreatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Date de l'autorisation:

2019-08-06

Notice patient

                                SAFETY INFORMATION CARD FOR PATIENTS
UNDER ANTICOAGULANT TREATMENT WITH RIVAROXABAN TARO
RIVAROXABAN TARO 2.5 MG
RIVAROXABAN TARO 10 MG
RIVAROXABAN TARO 15 MG
RIVAROXABAN TARO 20 MG
Keep this card with you at all times
Present this card to every doctor or dentist
at the beginning of the visit
THE PATIENT CARRYING THIS CARD IS UNDER ANTICOAGULANT TREATMENT
WITH RIVAROXABAN TARO
Name _________________________________________________
Address _______________________________________________
Date of birth ___________________ Weight ___________________
Information regarding concomitant diseases and medications
_____________________________
INFORMATION IN CASE OF EMERGENCY
IN CASE OF EMERGENCY, PLEASE INFORM THE TREATING DOCTOR
______________________
Telephone ______________________________________________
PLEASE ALSO NOTIFY:
Name _____________________Relationship ______________
Telephone ______________________________________________
Emergency phone (clinic/first aid) _________________________
INFORMATION REGARDING USE OF THE MEDICINE
Treatment start date __________________________________
Indication ___________________________________________
Dosage and administration regimen ______________________
Renal function at treatment onset (creatinine clearance mL/min)
___________________________________________________
INFORMATION FOR HEALTHCARE PROVIDERS:
Measuring INR is not suitable for assessment of the anticoagulant
activity of Rivaroxaban Taro and should therefore not be used for this
purpose.
INFORMATION ON ANTICOAGULANTS AND GUIDANCE FOR THE PATIENT

The anticoagulant, Rivaroxaban Taro, is a blood thinner, which
protects you from the development of dangerous blood clots.

Rivaroxaban Taro must be taken exactly as prescribed by your
doctor. To ensure optimal protection from blood clots, you
should strictly comply with the administration schedule as
recommended by your doctor and do not skip any dose,
unless instructed by your doctor.

Do not stop taking Rivaroxaban Taro without consulting your
doctor, as your 
                                
                                Lire le document complet
                                
                            

Documents dans d'autres langues

Notice patient Notice patient arabe 28-09-2023
Notice patient Notice patient hébreu 28-09-2023

Rechercher des alertes liées à ce produit

Afficher l'historique des documents